title: Two Takayasu arteritis patients successfully treated with infliximab: a potential disease-modifying agent?
authors.forename: A
authors.initials: A
authors.lastname: Della Rossa
authors.forename: A
authors.initials: A
authors.lastname: Tavoni
authors.forename: G
authors.initials: G
authors.lastname: Merlini
authors.forename: C
authors.initials: C
authors.lastname: Baldini
authors.forename: M
authors.initials: M
authors.lastname: Sebastiani
authors.forename: M
authors.initials: M
authors.lastname: Lombardi
authors.forename: D
authors.initials: D
authors.lastname: Neglia
authors.forename: S
authors.initials: S
authors.lastname: Bombardieri
mesh_terms: D000293:Adolescent; D000328:Adult; D000911:Antibodies, Monoclonal / Q000627:therapeutic use*; D018501:Antirheumatic Agents / Q000627:therapeutic use*; D005260:Female; D006801:Humans; D000069285:Infliximab; D013625:Takayasu Arteritis / Q000188:drug therapy*; D014409:Tumor Necrosis Factor-alpha / Q000037:antagonists & inhibitors
chemical_list: D000911:Antibodies, Monoclonal; D018501:Antirheumatic Agents; D014409:Tumor Necrosis Factor-alpha; D000069285:Infliximab